OmniAb (OABI) Gains from Investment Securities (2022 - 2026)
OmniAb's (OABI) quarterly Gains from Investment Securities came in at -$320000.0 in Q1 2026, up 61.63% year-on-year from -$197982.2 in Q1 2025, and down 358.06% on a QoQ basis from $124000.0 in Q4 2025.
OmniAb (OABI) Gains from Investment Securities (2022 - 2026) Analysis & Trends
OmniAb (OABI) has 5 years of Gains from Investment Securities data on file, last reported at -$320000.0 in Q1 2026.
- On a quarterly basis, Gains from Investment Securities rose 61.63% year-over-year to -$320000.0 in Q1 2026; TTM through Mar 2026 was $839000.0, a 124.54% increase from a year earlier, with the FY2025 full-year figure at $325000.0, up 112.76% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at -$320000.0, down from $124000.0 in the prior quarter.
- Over the last five years, Gains from Investment Securities for OABI reached as high as $1.1 million in Q2 2025 and fell as low as -$2.6 million in Q2 2024.
- Historically, Gains from Investment Securities has averaged -$204411.8 across 5 years, with a median of -$66000.0 in 2023.
- On a YoY basis, Gains from Investment Securities climbed as much as 345.24% in 2024 and fell as far as 6477.5% in 2024.
- Year by year, Gains from Investment Securities stood at -$105000.0 in 2022, then jumped by 37.14% to -$66000.0 in 2023, then sank by 107.58% to -$137000.0 in 2024, then surged by 190.51% to $124000.0 in 2025, then plunged by 358.06% to -$320000.0 in 2026.
- Per Business Quant data, the three most recent Gains from Investment Securities figures were -$320000.0 in Q1 2026, $124000.0 in Q4 2025, and -$24000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | OmniAb | 260.98 Mn | 211.91 Mn | 14.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -320,000.00 |
| Mar 31, 2026 | -320,000.00 |
| Dec 31, 2025 | 124,000.00 |
| Dec 31, 2025 | 124,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | 1.06 Mn |
| Jun 30, 2025 | 1.06 Mn |
| Mar 31, 2025 | -834,000.00 |
| Mar 31, 2025 | -834,000.00 |
| Dec 31, 2024 | -137,000.00 |
| Dec 31, 2024 | -137,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Sep 30, 2024 | 103,000.00 |
| Jun 30, 2024 | -2.55 Mn |
| Jun 30, 2024 | -2.55 Mn |
| Mar 31, 2024 | 38,000.00 |
| Mar 31, 2024 | 38,000.00 |
| Dec 31, 2023 | -66,000.00 |
| Dec 31, 2023 | -66,000.00 |